Research Reports

Healthcare

icon
Home » Reports » Bivalirudin And Desmopressin Market Global Demand Analysis Opportunity Outlook 2024
Market Research Report

Bivalirudin and desmopressin Market : Global Demand Analysis & Opportunity Outlook 2024

Published On : 01:08 AM, 2nd November, 2017 REP-ID-266 Category: Healthcare

Bivalirudin and desmopressin Market Overview

Bivalirudin is a thrombin –inhibiting oligopeptide that was developed through rational drug as a hirudin analogue.  It is a thrombin inhibitor consisting of 20 –amino acid structure combining a carboxy-terminal region that recognizes thrombin’s fibrin (ogen)-  binding sate.  It works by blocking of the formation of blood clots. Likewise, desmopressin is an antidiuretic harmone. It works by causing the kidneys to produce less urine. Bivalirudin is used as an anticoagulant in the patients with unstable angina who are undergoing percutaneous transluminal coronary angioplasty (PTCA) and in patients undergoing percutaneous coronary intervention (PCI). Moreover, Bivalirudin is used in conjuction with other medicines. Further, desmopressin is used to manage temporarily increased thirst and urination caused by head injury.

Market Size and Forecast

The market is expected to increase significantly over the forecast period 2017-2024. The bivalirudin is facing increased demand due to its application in the treatment of coronary artery disease and cancer.  Likewise, the demand for desmopressin is increasing due to its use in bedtime wetting and nocturia.

Market Segmentation:

Our in depth analysis of the bivalirudin and desmopressin market includes the following segments:

By Use:

  • Percutaneous Transluminal Coronary Angioplasty (PTCA) Procedures
  • Percutaneous Coronary Intervention (PCI) Procedures
  • Others

The global bivalirudin and desmopressin market is further classified on the basis of region as follows:

By Region:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Western and Eastern Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, Rest of Western Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of Asia) Market size, Y-O-Y growth & Opportunity Analysis.

Bivalirudin and desmopressin Market

Growth Drivers and Challenges

The market growth is driven by the rise in the number of the cases of cardiovascular diseases. According to the American Heart Association, the number of the adults living with the heart failure has increased from 5.7 million (2009-12) to about 6.5 million (2011-2014). Further, the cardiovascular diseases are on rise thereby leading to the increased number of deaths across the world. The cardiovascular diseases include coronary artery disease, high blood pressure and stroke. The patients with ST-elevation myocardial infarction (STEMI) is often achieved via primary percutaneous coronary intervention (PCI), thus reducing major adverse cardiovascular diseases. Adjunctive antithrombotic and antiplatelet therapies are used during PCI to reduce MACE rates. The most commonly used agents include low unfractioned heparin. These agents reduce the rates of peri-procedural ischemic and thrombotic events, but these agents produce complications in the form of increased bleeding, but bivalirudin has emerged as a safe alternative to heparin and helps in reducing the risk of coronary artery disease. Moreover, bivalirudin has advantages over the heparin including reduced rates of mortality, cardiovascular mortality and major bleeding events. Therefore, this has led to the adoption of bivalirudin as a drug for the treatment of coronary artery disease, thus leading to the expansion of the bivalirudin market.  The increase in the number of cancer patients is another reason that is driving the growth of bivalirudin market. According to the World Health Organization (WHO), approximately 14 million cases came into the light in 2012. Moreover, the cancer is second leading cause of the death globally, and was responsible for 8.8 million deaths in 2015. The expansion of the desmopressin market is driven by the increasing number of nocturia cases among elderly men and women. Nocturia is a lower urinary tract symptom which involves the need for passing urine at night, resulting in the disturbance of sleep. As a result, it frequently impacts upon the quality of life (QoL) and wellbeing of individuals. The prevalence increases with the age and has reported to be as high as 77% and 94% in elderly women and men respectively, thus leading to the expansion of the desmopressin market. Desmopressin works as an effective treatment for patients with nocturia. The antidiuretic effect of desmopressin decreases the number of the night voids and prolongation of the sleep period as compared to placebo. However, the market growth of Bivalirudin is hindered by various reasons including the cost and the reluctance to change from existing anti-thrombotic agents used.

Key Players

  • Pfizer, Inc. (US)
    • Company Overview
    • Key Product Offerings
    • Business Strategy
    • SWOT Analysis
    • Financials
  • Hainan Shuangcheng Pharmaceuticals Co. Ltd.
  • AmbioPharm Inc.
  • Abott India Limited (India)
  • The Medicines Company
  • Sun Pharmaceuticals Industries Limited
  • Ferring Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Chengdu Shengnuo Biopharm Co. Ltd.
  • ScinoPharm Taiwan Ltd

Scope and Context

Overview of the Parent Market

Analyst View

Segmentation

The Global Bivalirudin and Desmopressin Market is segmented as follows:

  • By Use Market Size & Y-O-Y Growth Analysis
  • By Region Market Size & Y-O-Y Growth Analysis

Market Dynamics

Supply & Demand Risk

Competitive Landscape

Porter’s Five Force Model

Geographical Economic Activity

Key Players (respective SWOT Analysis) and their Strategies and Product Portfolio

Recent Trends and Developments

Industry Growth Drivers and Challenges

Key Information for Players to establish themselves in current dynamic environment

 

   Key Answers Captured in Report?
Which geography would have better demand for product/services?
What are the strategies adopted by big players in the regional market?
Which country would see the steep rise in CAGR & year-on-year (Y-O-Y) growth?
What is the current & expected market size in next five years?
What is the market feasibility for long term investment?
What opportunity the country would offer for existing and new players in the market?
What is risk involved for suppliers in the geography?
What factors would drive the demand for the product/service in near future?
What is the impact analysis of various factors in the market growth?
What are the recent trends in the regional market and how successful they are?

SELECT LICENSE TYPE

KEY BENEFITS

  • DIRECT ANALYST ASSISTANCE

    Direct access to analyst to help you understand the market in a better way to handle your critical question

  • CUSTOMIZE AS PER YOUR NEED

    Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved

  • DISCOUNT ON CUSTOMISATION

    Get 10% free customization

  • QUALITY ASSURED

    Great focus on accuracy and quality of the research

Connect With Us

Call us

(U.S.) - +1 646 586 9123
(Canada) - +1 437 889 3230
(U.K.) - +44 203 608 5919
(India) - + 91 120 660 5495
Email: info@researchnester.com

Ask The Analyst

Delivery Center

1014, 10th Floor, Tower A1,
Ansal Corporate Park, Plot no 7A/1,
Sector 142 Noida., 201301 India
info@researchnester.com

US Office

1820 Avenue M, Suite# 1113,
Brooklyn, New York 11230
Phone : +1 646 586 9123
info@researchnester.com

Canada (Toronto)

Phone : +1 437 889 3230
info@researchnester.com

UK Office (London)

Phone : +44 203 608 5919
info@researchnester.com

Copyright © 2018 Research Nester. All rights reserved

Top